keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/28643982/-current-surgical-treatment-for-hepatocellular-carcinoma-critical-appraisal-of-current-guidelines
#1
Daniel Clerc, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
Hepatocellular carcinoma (HCC) management has evolved in the last decades. Current available treatments include interventional radiology like radiofrequency ablation, transarterial chemoembolization or Yttrium 90 radioembolization. Surgery, when possible, has been proven to be the most effective treatment in reducing the risk of long-term local recurrence. American and European societies (AASLD, EASL, respectively) guidelines for the management of HCC endorse The Barcelona Clinic Liver Cancer (BCLC) treatment allocation system...
June 14, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28643305/-interventional-therapy-of-colorectal-liver-metastasis
#2
Qi Zhang, Gaojun Teng
Colorectal liver metastasis (CRLM) is one of the most difficult and key points in the treatment of colorectal cancer. Approximately 50% to 60% of patients diagnosed as colorectal cancer develops metastasis, and 80% to 90% of CRLM is unresectable. Surgical resection is the first-line treatment for CRLM, while it is only suitable for about 15% patients. Systemic chemotherapy can prolong the survival of CRLM patients, however, a part of CRLM patients are resistant to chemotherapy. With the development of technology and the update of clinical evidence, individual therapy with target drugs and multidisciplinary treatment (MDT) have became a tendency, and minimally invasive interventional therapy has gained more acceptance in the MDT mode of the treatment for CRLM...
June 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28624008/a-systematic-review-of-yttrium-90-radioembolization-for-unresectable-liver-metastases-of-melanoma
#3
REVIEW
Zhongzhi Jia, Guomin Jiang, Chunfu Zhu, Kai Wang, Shaoqin Li, Xihu Qin
PURPOSE: To assess the effectiveness of yttrium-90 ((90)Y) radioembolization in the treatment of unresectable liver metastases of melanoma. METHODS: PubMed and EMBASE were systemically searched for all English language studies related to (90)Y radioembolization for unresectable liver metastases of melanoma, including clinical trials, observational studies, and abstracts from conferences, published between January 1991 and March 2016. RESULTS: A total of 12 reports (7 observational studies and 5 abstracts from conferences) involving 255 patients were included in the analysis...
July 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28608276/a-comparison-of-yttrium-90-microsphere-radioembolization-to-hepatic-arterial-infusional-chemotherapy-for-patients-with-chemo-refractory-hepatic-colorectal-metastases
#4
REVIEW
Andrea Cercek, Vyacheslav Gendel, Salma Jabbour, Dirk Moore, Chunxia Chen, John Nosher, Marinela Capanu, Joanne F Chou, Taryn Boucher, Nancy Kemeny, Darren R Carpizo
Patients with unresectable hepatic colorectal metastases who become chemo-refractory have limited treatment options. Systemic chemotherapies such as TAS102 and regorafenib have been used in the refractory setting, but with only modest improvement in overall survival compared to best supportive care. In patients with liver-only or liver-dominant disease, direct chemotherapy to the liver such as hepatic artery infusional (HAI) chemotherapy and radioembolization (yttrium-90 (Y90)) should be considered. Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90...
July 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28605614/medical-management-of-hepatocellular-carcinoma
#5
Nicole E Rich, Adam C Yopp, Amit G Singal
Hepatocellular carcinoma (HCC) typically occurs in patients with advanced liver disease, so therapeutic decisions must account for the degree of underlying liver dysfunction and patient performance status in addition to tumor burden. Curative treatment options, including liver transplantation, surgical resection, and local ablative therapies, offer 5-year survival rates exceeding 60% but are restricted to patients with early-stage HCC. Surgical resection and local ablative therapies are also limited by high recurrence rates, highlighting a need for adjuvant and/or neoadjuvant therapies...
June 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28598685/radioembolization-for-unresectable-intrahepatic-cholangiocarcinoma-review-of-safety-response-evaluation-criteria-in-solid-tumors-1-1-imaging-response-and-survival
#6
Nathaniel C Swinburne, Derek M Biederman, Cecilia Besa, Nora E Tabori, Aaron M Fischman, Rahul S Patel, Francis Scott Nowakowski, Ganesh Gunasekaran, Myron E Schwartz, Robert A Lookstein, Edward Kim
The optimal palliative treatment for unresectable intrahepatic cholangiocarcinoma (ICC) remains controversial. While selective internal radiation therapy (SIRT) using yttrium-90 microspheres is a well-accepted treatment for hepatocellular carcinoma, data related to its use for locally advanced ICC remain relatively scarce. Twenty-nine patients (mean age 66 ± 11 years; 15 female) with unresectable biopsy-proven ICC treated with SIRT between June 2008 and April 2015 were retrospectively evaluated for post-treatment toxicity, overall survival, and imaging response using response evaluation criteria in solid tumors (RECIST) 1...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28584948/evaluation-of-visualization-using-a-50-50-contrast-media-glucose-5-solution-technique-for-radioembolization-as-an-alternative-to-a-standard-sandwich-technique
#7
Karolin J Paprottka, Andrei Todica, Harun Ilhan, Johannes Rübenthaler, Franziska Schoeppe, Marlies Michl, Volker Heinemann, Peter Bartenstein, Maximilian F Reiser, Philipp M Paprottka
BACKGROUND: Radioembolization (RE) with (90)yttrium ((90)Y) resin microspheres generally employs a sandwich technique with separate sequential administration of contrast medium (CM), followed by vehicle (e.g., glucose 5% [G5] solution), then (90)Y resin microspheres (in G5), then G5, and then CM again to avoid contact of CM and microspheres under fluoroscopic guidance. This study evaluates the visualization quality and safety of a modified sandwich technique with a 50/50-mixture of CM (Imeron 300) and G5 for administration of (90)Y resin microspheres...
June 5, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28579679/yttrium-90-radioembolization-for-metastatic-colorectal-cancer-outcomes-by-number-of-lines-of-therapy
#8
REVIEW
Andrew Marsala, Edward W Lee, Siddharth A Padia
Metastatic colorectal cancer represents the most common liver malignancy, and imparts a very poor prognosis for those who develop this disease. Unlike primary liver tumors such as hepatocellular carcinoma, which largely develops in patients with underlying cirrhosis, most metastatic liver tumor patients have normal underlying liver function. Owing to this, most will succumb to tumoral replacement of the liver rather than from underlying liver dysfunction. Radioembolization represents a treatment modality that can be used in multiple fashions to treat one or both lobes of the liver...
June 2017: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/28579678/transarterial-chemoembolization-and-radioembolization-across-barcelona-clinic-liver-cancer-stages
#9
REVIEW
Joseph Titano, Amir Noor, Edward Kim
Transarterial chemoembolization (TACE) is a well-established treatment for hepatocellular carcinoma (HCC). TACE has a clearly delineated role within the Barcelona Clinic Liver Cancer (BCLC) staging framework, and TACE has been shown to bridge patients to transplantation and to downsize patients' tumor burden to meet transplantation criteria. Radioembolization (RE) also has an evolving role in the treatment of HCC. RE has evidence-based applications across the range of BCLC stages ranging from segmentectomy for patients with solitary lesions not amenable to ablation to lobar therapy for patients with multifocal HCC, and to treatment of advanced disease with portal vein thrombosis...
June 2017: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/28579676/decision-making-intra-arterial-therapies-for-cholangiocarcinoma-tace-and-tare
#10
REVIEW
Brian M Currie, Michael C Soulen
The incidence of intrahepatic cholangiocarcinoma (ICC) has been increasing in recent years and now represents the second most common primary hepatic cancer in the United States. The prognosis is dismal without surgical resection. In patients ineligible to receive curative treatments, locoregional therapies represent a diverse array of techniques that can stabilize or reverse tumor progression to improve overall survival and reduce tumor-related symptoms. Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have been demonstrated to be efficacious methods for this patient population...
June 2017: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/28578290/-131-i-labeled-chitosan-hydrogels-for-radioembolization-a-preclinical-study-in-small-animals
#11
Hyosook Hwang, Kwang Il Kim, JeongIl Kwon, Byoung Soo Kim, Hwan-Seok Jeong, Su Jin Jang, Phil-Sun Oh, Ho Sung Park, Seok Tae Lim, Myung-Hee Sohn, Hwan-Jeong Jeong
INTRODUCTION: The purpose of the study was to examine potential of (131)I-labeled chitosan hydrogels (Chi) for treatment of liver cancer. METHODS: Orthotopic hepatoma was induced by McA-RH7777-fLuc cells (1×10(7)) that were injected into the left hepatic lobe of rats. Ten days later, tumor-bearing rats evidenced by bioluminescence received (125)I-labeled Chi with left hepatic artery access. Pharmacokinetics and excretion (n=8) and biodistribution (n=6/time point) were studied after injection...
May 25, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28547124/erratum-to-unresectable-hepatocellular-carcinoma-radioembolization-versus-chemoembolization-a-systematic-review-and-meta-analysis
#12
Laila Lobo, Danny Yakoub, Omar Picado, Caroline Ripat, Fiorella Pendola, Rishika Sharma, Rana ElTawil, Deukwoo Kwon, Shree Venkat, Loraine Portelance, Raphael Yechieli
No abstract text is available yet for this article.
May 25, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28534347/recent-perspectives-of-management-of-breast-cancer-metastasis-an-update
#13
Qingzhong Tian, Yun Wang, Hao Guo, Guangwei Xie, Jin Li, Minkang Zhang, Qianjin Zhang, Qingliang Meng
Breast cancer is the leading cause of cancer related deaths in women and one of the most common cancers globally. The major obstacle in the management of breast cancer, especially at advanced stages, is metastasis. Metastasis in the advanced stages of breast cancer could decrease survival to approximately 5 years. The reasons could include lack of targeted receptors or chemotherapeutic agents for the management of advanced-stage breast cancer metastasis. The new emerging avenues for the management of this deadly pathological state include local manipulations like radiofrequency ablation (RFA), microwave thermotherapy, cryosurgery (cryotherapy), chemoembolization, radioembolization, breast surgery, or metastasectomy...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28534185/erratum-to-yttrium-90-radioembolization-for-unresectable-combined-hepatocellular-cholangiocarcinoma
#14
Lauren S Chan, Daniel Y Sze, George A Poultsides, John D Louie, Mohammed A Abdelrazek Mohammed, David S Wang
No abstract text is available yet for this article.
May 22, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28527884/adjuvant-medications-that-improve-survival-after-locoregional-therapy
#15
F Edward Boas, Etay Ziv, Hooman Yarmohammadi, Karen T Brown, Joseph P Erinjeri, Constantinos T Sofocleous, James J Harding, Stephen B Solomon
PURPOSE: To determine if outpatient medications taken at the time of liver tumor embolization or ablation affect survival. MATERIALS AND METHODS: A retrospective review was done of 2,032 liver tumor embolization, radioembolization, and ablation procedures performed in 1,092 patients from June 2009 to April 2016. Pathology, hepatocellular carcinoma (HCC) stage (American Joint Committee on Cancer), neuroendocrine tumor (NET) grade, initial locoregional therapy, overall survival after initial locoregional therapy, Child-Pugh score, Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index, and outpatient medications taken at the time of locoregional therapy were analyzed for each patient...
May 17, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28509806/advances-in-management-of-hepatocellular-carcinoma
#16
Manon Allaire, Jean-Charles Nault
PURPOSE OF REVIEW: Hepatocellular carcinoma (HCC) is one of the leading causes of death by cancer worldwide due to a dismal prognosis. The aim of this review is to summarize the main advances in the pathophysiology and management of HCC. RECENT FINDINGS: Genomic analysis has recently delineated the key signaling pathways aberrantly deregulated in HCC (telomere maintenance, cell cycle gene, Wnt/β-catenin, epigenetic modifier, oxidative stress etc.). Major advances in the clinical care of patients with HCC are helping to refine the diagnosis algorithm and tumor staging...
July 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28509566/respiratory-motion-during-90-yttrium-pet-contributes-to-underestimation-of-tumor-dose-and-overestimation-of-normal-liver-tissue-dose
#17
Line Ausland, Mona-Elisabeth Revheim, Arne Skretting, Caroline Stokke
Background Yttrium-90 dosimetry after radioembolization is reliant on accurate quantitative imaging of the microsphere deposition. Previous studies have focused on the correction of geometrical resolution effects. Purpose To uncover additional effects of respiratory motion. Material and Methods Mathematical models describing spherical tumors were formed and two blurring effects, limited geometrical resolution and respiratory motion, were simulated. The virtual images were used as basis for dose volume histogram estimations by convolving the radioactivity representations with a dose point kernel...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28500460/prophylactic-temporary-occlusion-of-the-cystic-artery-using-a-fibered-detachable-coil-during-90-y-radioembolization
#18
Jin Woo Choi, Min Young Yoo, Hyo-Cheol Kim, Jin Chul Paeng, Yoon Jun Kim, Jin Wook Chung
PURPOSE: To address the feasibility of prophylactic temporary occlusion of the cystic artery using a detachable coil during (90)Y radioembolization. MATERIALS AND METHODS: From January 2012 to October 2016, nine patients underwent temporary occlusion of the cystic artery during (90)Y radioembolization. Based on the planning hepatic angiography, a detachable coil was deployed into the cystic artery, which arose from a more distal level (e.g., right anterior hepatic artery) than its usual origin, but the proximal 1 cm was left inside the microcatheter...
May 12, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28494530/radioembolization-for-the-treatment-of-hepatocellular-carcinoma
#19
Hyo-Cheol Kim
Transarterial radioembolization (TARE) with yttrium 90 (90Y), an intra-arterial procedure performed by interventional radiologists, has begun being utilized in managing hepatocellular carcinoma (HCC) in Korea. There are two available TARE products: glass and resin microspheres with different physical characteristics. All patients undergoing TARE must be assessed with clinical examination and laboratory tests as well as a thorough angiographic evaluation. TARE is safe and effective in the treatment of unresectable HCC, as it has longer time-to-progression, greater ability to downsize tumors for liver transplantation, less post-embolization syndrome, and shorter hospitalization compared with chemoembolization...
May 10, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28490991/other-non-surgical-treatments-for-liver-cancer
#20
Paul Revel-Mouroz, Philippe Otal, Marion Jaffro, Antoine Petermann, Olivier Meyrignac, Pierre Rabinel, Fatima-Zohra Mokrane
Interventional radiology plays a major role in the modern management of liver cancers, in primary hepatic malignancies or metastases and in palliative or curative situations. Radiological treatments are divided in two categories based on their approach: endovascular treatment and direct transcapsular access. Endovascular treatments include mainly three applications: transarterial chemoembolization (TACE), transarterial radioembolization (TARE) and portal vein embolization (PVE). TACE and TARE share an endovascular arterial approach, consisting of a selective catheterization of the hepatic artery or its branches...
March 2017: Reports of Practical Oncology and Radiotherapy
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"